- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 782642, 10 pages
Camel Milk Modulates the Expression of Aryl Hydrocarbon Receptor-Regulated Genes, Cyp1a1, Nqo1, and Gsta1, in Murine hepatoma Hepa 1c1c7 Cells
1Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, 11451 Riyadh, Saudi Arabia
2Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada T6G 2E1
3Department of Pharmacology, College of Medicine, King Saud University, 11461 Riyadh, Saudi Arabia
Received 6 September 2011; Revised 24 October 2011; Accepted 8 November 2011
Academic Editor: Ikhlas A. Khan
Copyright © 2012 Hesham M. Korashy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
There is a traditional belief in the Middle East that camel milk may aid in prevention and treatment of numerous cases of cancer yet, the exact mechanism was not investigated. Therefore, we examined the ability of camel milk to modulate the expression of a well-known cancer-activating gene, Cytochrome P450 1a1 (Cyp1a1), and cancer-protective genes, NAD(P)H:quinone oxidoreductase 1 (Nqo1) and glutathione S-transferase a1 (Gsta1), in murine hepatoma Hepa 1c1c7 cell line. Our results showed that camel milk significantly inhibited the induction of Cyp1a1 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the most potent Cyp1a1 inducer and known carcinogenic chemical, at mRNA, protein, and activity levels in a concentration-dependent manner. In addition, camel milk significantly decreased the xenobiotic responsive element (XRE)-dependent luciferase activity, suggesting a transcriptional mechanism is involved. Furthermore, this inhibitory effect of camel milk was associated with a proportional increase in heme oxygenase 1. On the other hand, camel milk significantly induced Nqo1 and Gsta1 mRNA expression level in a concentration-dependent fashion. The RNA synthesis inhibitor, actinomycin D, completely blocked the induction of Nqo1 mRNA by camel milk suggesting the requirement of de novo RNA synthesis through a transcriptional mechanism. In conclusion, camel milk modulates the expression of Cyp1a1, Nqo1, and Gsta1 at the transcriptional and posttranscriptional levels.
The aryl hydrocarbon receptor (AhR), a cytosolic ligand-activated transcriptional factor, belongs to the basic-helix-loop-helix (bHLH)/Per-ARNT-Sim (PAS) family of transcription proteins, which are involved in regulation of cell differentiation and proliferation [1, 2]. Mechanistically, AhR is located in the cytoplasm bound with heat shock protein-90 (HSP90) and AhR interacting protein (AIP) forming inactive complex. Activation of AhR upon binding with its ligands, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a polycyclic aromatic hydrocarbon (PAH), causes dissociation of HSP90 and AIP from the activated ligand-receptor complex, subsequently leading to translocation of the complex into nucleus. In the nucleus, the ligand-receptor complex dimerizes with AhR nuclear translocator (ARNT), which subsequently binds to xenobiotic-responsive element (XRE) located in the promoter region of so-called AhR-regulated genes resulting in promoting its transcription and protein translation processes [3, 4].
The AhR-regulated gene batteries include phase I xenobiotic metabolizing enzymes such as the cytochrome P450 1A1 (CYP1A1), CYP1A2, CYP1B1 and phase II enzymes such as NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione S-transferase A1 (GSTA1), uridine diphosphate glucuronosyltransferase 1A6, and aldehyde dehydrogenase-3 [3, 4]. Among these genes, CYP1A1 plays a particular role in bioactivating procarcinogens into carcinogen and toxic metabolites and hence is considered as cancer-activating gene , whereas the NQO1 and GSTA1 catalyze reduction of several environmental contaminants and endogenous compounds that maintain endogenous antioxidants, such as ubiquinone and vitamin E, to protect tissues against mutagens, carcinogens, and oxidative stress damage [6, 7]. Accordingly, one of the strategies for protecting human cells and tissues from the toxic effects of carcinogenic and cytotoxic metabolites generally include attenuation of the carcinogen-activating genes, CYP1A1 signaling pathways, and/or enhancing the adaptive mechanisms by increasing the expression of detoxification and antioxidant genes, such as NQO1 and GSTA1 .
Chemoprevention by dietary constituents in the form of functional food has a well-established beneficial role in health promotion and emerged as a novel approach to control cancers . Camel’s milk is different from other ruminant milk, having low cholesterol, lactoferrin, low sugar, high minerals (sodium, potassium, iron, copper, zinc and magnesium), high vitamin C, B2, A, and E, low protein, and high concentrations of insulin. Recent studies have reported that camel milk is the most active milk among other species against E. coli, Staphylococcus aureus, Salmonella typhimurium, and rotavirus [10, 11]. In addition, it has been demonstrated that milk, in addition to secretory IgA and IgM, also contains numerous nonantibody components that possess antiviral activity, including lactoferrin .
Until recently, it is traditionally claimed that drinking camel milk may help to fight against serious diseases and cure numerous cases of cancer; however, this claim has never been exposed to scientific scrutiny investigation. Therefore, the main objective of the current study was to explore the capacity of camel milk to modulate the expression of Cyp1a1, Nqo1, and Gsta1 genes as target for cancer prevention in murine hepatoma Hepa 1c1c7 cells.
2. Materials and Methods
7-Ethoxyresorufin (7ER), Dulbecco’s Modified Eagle’s Medium (DMEM), protease inhibitor cocktail, sulforaphane (SNF), resveratrol (RES), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and rabbit anti-goat IgG peroxidase secondary antibody were purchased from Sigma-Aldrich (St. Louis, MO). 2,3,7,8-Tetrachlorodibenzo-p-dioxin, >99% pure, was purchased from Cambridge Isotope Laboratories (Woburn, MA). Resorufin and 100 × vitamin supplements were purchased from ICN Biomedicals Canada (Montreal, QC). TRIzol and Lipofectamine 2000 reagents were purchased from Invitrogen (Carlsbad, CA). The High-Capacity cDNA reverse transcription kit and SYBR Green PCR Master Mix were purchased from Applied Biosystems (Foster City, CA). Actinomycin D (Act-D) was purchased from Calbiochem (San Diego, CA). Dual-Luciferase Reporter Assay System was obtained from Promega Corporation (Madison, WI). Chemiluminescence Western blotting detection reagents were obtained from GE Healthcare Life Sciences (Piscataway, NJ). Nitrocellulose membrane was purchased from Bio-Rad Laboratories (Hercules, CA). Cyp1a1 goat anti-mouse polyclonal primary antibody, glyceraldehyde-3-phosphate dehydrogenase (Gapdh) rabbit anti-goat polyclonal antibody, and anti-rabbit IgG peroxidase secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals were purchased from Fisher Scientific Co. (Toronto, ON).
2.2. Milk Sample Collection and Preparation
Camel milk was collected aseptically from five healthy domestic camels (Camelus dromedaries). The camel milk was collected from farm and desert living animals. The collection of milk was usually conducted during the feeding time and was performed by experienced attendants. Milk was allowed to flow directly into sterile stainless steel containers and then transferred to glass vials. Camel samples were transported to the laboratory as soon as practical (<4 h) and were frozen at −80°C. Aqueous portion (fat-free, skimmed milk) was removed from the lipids (cream) as described before . Briefly, aliquots of pooled milk samples were centrifuged at 1400 ×g for 30 minutes at 4°C, thereafter, the creamy layer consisting largely of fat was removed by filtration through a glass wool plug in a Pasteur pipette. Camel milk was collected and kept in −80°C freezer until use.
2.3. Cell Culture and Treatments
Murine hepatoma Hepa 1c1c7 cells (American Type Culture Collection, Manassas, VA) were maintained in DMEM, without phenol red supplemented with 10% heat-inactivated fetal bovine serum, 20 M L-glutamine, 100 IU/mL penicillin, 10 g/mL streptomycin, 0.1 mM nonessential amino acids, and vitamin supplement solution. Cells were grown in 75 cm2 tissue culture flasks at 37°C under a 5% CO2 humidified environment.
Hepa 1c1c7 cells were plated onto 96- and six-well cell culture plates in DMEM culture media for the mRNA, protein, and catalytic activity assays. In all experiments, the cells were pretreated for indicated time interval in serum-free media with various concentrations of camel milk in the presence or absence of TCDD as indicated. Stock solutions of TCDD were prepared in dimethyl sulfoxide (DMSO) and stored at −20°C, in which the concentration of DMSO did not exceed 0.05% (v/v).
2.4. Cytotoxicity of Camel Milk
The effects of camel milk (fat-free) on Hepa 1c1c7 cell viability were determined by measuring the capacity of reducing enzymes present in viable cells to convert MTT salt to formazan crystals as described previously . Twenty-four hours after incubating the cells with the tested milk in the presence and absence of TCDD in a 96-well cell culture plate at 37°C under a 4% CO2 humidified incubator, the media were removed and a 100 L of serum-free medium containing 1.2 mM of MTT dissolved in phosphate-buffered-saline (PBS), pH 7.4, was added to each well. The plate was then incubated in a CO2 incubator at 37°C for 2 h. The media were then decanted off by inverting the plate, and a 100 L of isopropyl alcohol was added to each well, with shaking for 1 h to dissolve the formazan crystals. The color intensity in each well was measured at wavelength of 550 using BIO-TEK Instruments EL 312e microplate reader, Bio-Tek Instruments (Winooski, VT). The percentage of cell viability was calculated relative to control wells designated as 100% viable cells.
2.5. Determination of Cyp1a1 Enzymatic Activity
Cyp1a1-dependent 7-ethoxyresorufin (7ER) O-deethylase (EROD) activity was performed on intact living Hepa 1c1c7 cells using 7ER as a substrate . After incubation of the cells with increasing concentrations of fat-free camel milk for 24 h, media were aspirated and the cell monolayers were rinsed with PBS. Thereafter, 100 L of 2 M 7ER in assay buffer (0.05 M Tris, 0.1 M NaCl, pH 7.8) was then added to each well. Immediately, an initial fluorescence measurement () at excitation/emission (545 nm/575 nm) was recorded from each well using Baxter 96-well fluorometer (Deerfield, IL). The plates were then replaced in the incubator, and additional set of fluorescence measurements of the wells were recorded every 5 min for 20 min interval. The amount of resorufin formed in each well was determined by comparison with a standard curve of known concentrations. The working solution was then aspirated, the cells were rinsed twice with PBS, and 50 l of double de-ionized water was added to lyse the cells. After placing of the cell plates at −80°C for 30 min, the cell lysates were allowed to thaw, and protein levels were determined using a modified fluorescent assay . The rate of resorufin formation was expressed as pmol/min/mg protein.
2.6. RNA Extraction and cDNA Synthesis
Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's instructions and quantified by measuring the absorbance at 260 nm. RNA quality was determined by measuring the 260/280 ratio. Thereafter, first strand cDNA was synthesized using the High-Capacity cDNA reverse transcription kit (Applied Biosystems) according to the manufacturer's instructions. Briefly, 1 g of total RNA from each sample was added to a mix of 2.0 L of 10x reverse transcriptase buffer, 0.8 L of 25x dNTP mix (100 mM), 2.0 L of 10x reverse transcriptase random primers, 1.0 L of MultiScribe reverse transcriptase, and 3.2 L of nuclease-free water. The final reaction mix was kept at 25°C for 10 min, heated to 37°C for 120 min, heated for 85°C for 5 s, and finally cooled to 4°C .
2.7. Quantification of mRNA Expression by Real-Time Polymerase Chain Reaction (RT-PCR)
Quantitative analysis of specific mRNA expression was performed by RT-PCR by subjecting the resulting cDNA to PCR amplification using 96-well optical reaction plates in the ABI Prism 7500 System (Applied Biosystems). The 25 L reaction mix contained 0.1 L of 10 M forward primer and 0.1 L of 10 M reverse primer (40 nM final concentration of each primer), 12.5 L of SYBR Green Universal Master Mix, 11.15 L of nuclease-free water, and 1.25 L of cDNA sample. The primers used in the current study (Table 1) [17, 18] were purchased from Integrated DNA Technologies (IDT, Coralville, IA). Assay controls were incorporated onto the same plate, namely, no-template controls to test for the contamination of any assay reagents. The RT-PCR data was analyzed using the relative gene expression (i.e., ) method, as described in Applied Biosystems User Bulletin . The data are presented as the fold change in gene expression normalized to the endogenous housekeeping gene (-actin) and was determined using the equation: fold change = , where and .
2.8. Protein Extraction and Western Blot Analysis
Twenty-four hours after incubating the cells with increasing concentrations of camel milk (fat-free), the cells were washed once with cold PBS and collected by scraping in 100 L of lysis buffer (50 mM HEPES, 0.5 M NaCl, 1.5 mM MgCl2, 1 mM EDTA, 10% (v/v) glycerol, 1% Triton X-100, and 5 L/mL of protease inhibitor cocktail). The lysates were incubated on ice for 1 h with intermittent vortexing every 10 min, followed by centrifugation at 12,000 ×g for 10 min at 4°C. The supernatant was then stored at a −80°C freezer for later use in the Western blot analysis.
Western blot analysis was performed as described previously . For Cyp1a1 immuno-detection, 30 g of proteins from each treatment group were diluted with same amount (1 : 1) of 2X loading buffer (0.1 M Tris-HCl, pH 6.8, 4% SDS, 1.5% bromophenol blue, 20% glycerol, 5% β-mercaptoethanol), boiled and loaded onto a 10% SDS-polyacrylamide gel. Samples were electrophoresed at 120 V for 2 h, and the separated proteins were transferred to Trans-Blot nitrocellulose membrane (0.45 μm) in a buffer containing 25 mM Tri-HCl, 192 mM glycine, and 20% (v/v) methanol. Protein blots were blocked overnight at 4°C in a solution containing 5% skim milk powder, 2% bovine serum albumin, and 0.5% Tween-20 in TBS solution (0.15 M NaCl, 3 mM KCl, 25 mM Tris-base). Thereafter, the blocking solution was removed and the blots were rinsed three times in a wash buffer (0.1% Tween-20 in TBS). Proteins were detected by incubation with a primary polyclonal goat anti-mouse Cyp1a1 antibody for 2 h at 4°C in TBS containing 0.01% sodium azide and 0.05% Tween-20. The primary antibody solution was removed and blots were rinsed three times with a wash buffer, followed by incubation with horseradish peroxidase-conjugate rabbit anti-goat secondary antibody for 1 h at room temperature followed by washing as previously described. Antibody detection was performed using the enhanced chemiluminescence method. The intensity of Cyp1a1 bands was quantified, relative to the signals obtained for Gapdh, using Java-based image-processing software, ImageJ (W. Rasband (2005) National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/).
2.9. Transient Transfection and Luciferase Assay
Transient transfection and luciferase assay were carried out as described previously . Briefly, Hepa 1c1c7 cells (3 × 104 cells per well) were plated onto 12-well cell culture plates. Each well was cotransfected with 1.5 g of XRE-driven luciferase reporter plasmid pGudLuc 1.1 and 0.1 g of the renilla luciferase pRL-CMV vector, used for normalization. The pGudLuc 1.1 plasmid was provided as a gift from Dr. Michael S. Denison (University of California, Davis, CA), while pRL-CMV vector was obtained from Promega Corporation (Madison,WI). Transfection procedure was carried out using Lipofectamine 2000 reagent according to the manufacturer's instructions (Invitrogen), the luciferase assay was performed according to the manufacturer's instructions (Promega), and luciferase activity was reported as relative light unit of firefly luciferase to renilla luciferase (Fluc/Rluc).
2.10. Statistical Analysis
All results are presented as mean ± SEM. The comparative analysis of the results from various experimental groups with their corresponding controls was performed using SigmaStat for Windows, Systat Software Inc., (San Jose, CA). One-way analysis of variance (ANOVA) followed by Student-Newman-Keul’s test was carried out to assess the significant difference between different groups. The differences were considered significant when .
3.1. Effect of Camel Milk on Hepa 1c1c7 Cell Viability
To determine the cellular toxicity effects of camel milk (fat-free) in the presence and absence of TCDD on Hepa 1c1c7, cells were treated for 24 h with increasing concentrations of camel milk (0, 15, 25, 50, 100, and 200 L/mL) in the presence and absence of TCDD (1 nM) and the cell viability was determined by MTT assay. Figure 1 shows that neither camel milk alone nor with TCDD were toxic to Hepa 1c1c7 cells at all concentrations of camel milk used, with the exception of mixture of TCDD plus camel milk (200 L/mL) that significantly decreased cell viability by approximately 25%. Based on these results, concentrations of 0, 25, and 100 L/mL of fat-free camel milk in the presence and absence of TCDD were chosen to be used in the subsequent experiments.
3.2. Effect of Camel Milk on the TCDD-Mediated Induction of Cyp1a1 Catalytic Activity in Hepa 1c1c7 Cells
To determine the capacity of camel milk to alter the induction of Cyp1a1 catalytic activity by TCDD, Hepa 1c1c7 cells were preincubated with increasing concentrations of camel milk (fat-free) (0, 25, and 100 L/mL) or RES (25 M), a positive control, for 30 min before the incubation with 1 nM TCDD for additional 24 h. The TCDD 1 nM concentration was selected from our previous concentration-response study that caused maximum induction of Cyp1a1 gene without significant cell toxicity . Thereafter, Cyp1a1 activity was determined by EROD assay. Figure 2 shows that TCDD alone markedly induced Cyp1a1 enzymatic activity level by 180-fold. Furthermore, camel milk at all concentrations tested significantly inhibited the TCDD-mediated induction of Cyp1a1 activity by approximately 63% and 80% at the concentrations of 25 and 100 L/mL, respectively, (Figure 2). On the other hand, RES, a well-known AhR antagonist, significantly reduced the Cyp1a1 induction by TCDD (Figure 2). The observed inhibition of Cyp1a1 by camel milk (fat-free) particularly at the highest concretion is due to a direct effect of camel milk and not because of any cell toxicity (Figure 1).
3.3. Effect of Camel Milk on the TCDD-Mediated Induction of Cyp1a1 mRNA Level in Hepa 1c1c7 Cells
To determine whether the inhibitory effect of camel milk (fat-free) on the TCDD-mediated induction of Cyp1a1 activity (Figure 2) is attributed to a transcriptional mechanism, Cyp1a1 mRNA levels were determined in Hepa 1c1c7 cells treated for 6 h with TCDD (1 nM) in the presence and absence of different concentrations of camel milk (0, 25, and 100 L/mL) or RES (25 M) as positive control. Our results showed that TCDD significantly induced Cyp1a1 mRNA level by approximately 15-fold (Figure 3). Importantly, incubation of Hepa 1c1c7 cells with camel milk (fat-free) significantly decreased the TCDD-mediated induction of Cyp1a1 mRNA in a concentration-dependent manner (Figure 3). The maximum inhibition (90%) was observed at the highest concentration tested (100 L/mL) (Figure 3). Similar to Cyp1a1 activity, the positive control RES significantly decreased the TCDD-mediated induction of Cyp1a1 mRNA (Figure 3).
3.4. Effect of Camel Milk on the TCDD-Mediated Induction of Cyp1a1 Protein in Hepa 1c1c7 Cells
To further investigate whether the obtained inhibition on TCDD-mediated induction of Cyp1a1 mRNA levels by camel milk is translated into a functional Cyp1a1 protein, Western blot analysis was carried out. Total protein was isolated from Hepa 1c1c7 cells treated for 24 h with TCDD (1 nM) in the presence and absence of different concentrations of camel milk (fat-free) (0, 25, and 100 L/mL). Figure 4 shows that the induction of Cyp1a1 protein by TCDD (72-fold) was significantly reduced by camel milk (fat-free) by approximately 30% and 65% at concentrations of 25 and 100 L/mL, respectively. This pattern of inhibition is similar to what was observed at the activity and mRNA level (Figures 2 and 3).
Taken together, these results showed that camel milk stands prominently in its inhibition of the induction of Cyp1a1 gene expression at the activity, mRNA, and protein levels.
3.5. Effect of Camel Milk on XRE-Dependent Luciferase Activity
To explore the ability of fat-free camel milk to inhibit the AhR-dependent reporter gene expression, Hepa 1c1c7 cells were transiently cotransfected with the XRE-dependent luciferase reporter gene and renilla luciferase vector, which was used for normalization of transfection efficiency. Cells were then incubated for 24 h with TCDD (I nM) in the presence and absence of camel milk (100 L/mL). Our results showed that TCDD significantly induced XRE-dependent luciferase activity by approximately 7-fold (Figure 5). Importantly, camel milk (fat-free, 100 L/mL) completely blocked the induction of XRE-dependent luciferase activity by TCDD to its control level (Figure 5).
3.6. Effect of Camel Milk on Ho-1 mRNA in Hepa 1c1c7 Cells
The capacity of camel milk to inhibit TCDD-mediated induction of Cyp1a1 at the activity level more than at the protein levels prompted us to investigate the possible role of Ho-1, a rate-limiting enzyme of heme degradation, in this inhibitory effect. For this purpose, Ho-1 mRNA level was determined in Hepa 1c1c7 cells treated with increasing concentrations of camel milk (0, 25, and 100 L/mL) or SFN (5 M), as a positive control, for 6 h. Our results show that camel milk (fat-free) significantly increased the Ho-1 mRNA expression level by the highest concentration tested (100 L/mL) by approximately 3-fold (Figure 6). Similarly, SFN caused a 9-fold induction in Ho-1 mRNA level. These data may suggest a role for Ho-1 in camel milk-mediated effects.
3.7. Effect of Camel Milk on Nqo1 and Gsta1 mRNA Levels in Hepa 1c1c7 Cells
To further investigate whether camel milk (fat-free) is able to increase the expression of chemoprotective genes, Nqo1 and Gsta1 mRNA levels were measured in Hepa 1c1c7 cells treated for 6 h with camel milk (0, 25, and 100 L/mL) or SFN (5 M), as a positive control. Figure 7 shows that camel milk (fat-free) significantly induced Nqo1 and Gsta1 mRNA levels by approximately 2.5- and 8-fold, respectively, at the highest concentration tested (100 L/mL). A similar induction was observed with SFN, strong inducer of Nqo1 and Gsta1 (Figure 7).
3.8. Effect of Transcription Inhibitor, Act-D, on Camel-Milk-Induced Nqo1 mRNA Levels
To further investigate whether camel milk (fat-free) is able to increase the de novo Nqo1 RNA synthesis, Hepa 1c1c7 cells were treated with Act-D (5 g/mL, RNA synthesis inhibitor) immediately before the addition of camel milk (fat-free, 100 L/mL) for additional 6 h. Thereafter, Nqo1 mRNA was quantified by real-time PCR. If camel milk increases the amount of Nqo1 mRNA through a transcriptional mechanism, a decrease in the Nqo1 mRNA level would be expected. Figure 8 shows that Act-D slightly but significantly inhibited the constitutive expression of Nqo1 mRNA, whereas markedly blocked the camel milk-induced Nqo1 mRNA by approximately 70% (Figure 8).
The current study provides the first mechanistic evidence of the ability of camel milk to significantly inhibit the induction of Cyp1a1, a cancer-activating gene, and to induce Nqo1 and Gsta1, cancer protecting genes in Hepa 1c1c7 cells at the transcriptional and posttranscriptional levels.
One of the strategies for protecting human cells and tissues from the toxic effects of carcinogenic and cytotoxic metabolites include attenuation of the carcinogen-activating genes signaling pathways and/or enhancing the adaptive mechanisms by increasing the expression of detoxification and antioxidant genes. Accordingly, we hypothesize that camel milk exhibits anticancer effects by inhibiting the expression of Cyp1a1 and/or inducing Nqo1 and Gsta1 genes. Therefore, to test our hypothesis we examined the capacity of camel milk to (a) inhibit the induction of Cyp1a1 at the mRNA, protein, and activity levels, (b) induce the expression of Nqo1, and Gsta1 mRNA levels in Hepa 1c1c7 cells, and (c) explore the underlying molecular mechanism.
Several lines of evidence showed that induction of CYP1A1 is strongly correlated with increased incidence of several human colon, rectal, and lung cancers [23, 24]. In addition, studies on the carcinogenicity and mutagenicity of PAHs have demonstrated a significant role for the induction of CYP1A1 in bioactivating these environmental toxicants into their ultimate carcinogenic forms . Thus Cyp1a1 induction is considered a useful biomarker of exposure to carcinogenic substances . Accordingly, we have first examined the potential effect of camel milk on the expression of Cyp1a1 gene after induction by TCDD using EROD as a probe for Cyp1a1 activity . Our results showed that camel milk (fat-free) at all concentrations tested reduced Cyp1a1 EROD activity in a concentration-dependent manner (Figure 2). Importantly, the modulation of Cyp1a1 activity by camel milk is attributed to a decrease in transcriptional and translational regulation of Cyp1a1 gene. This was evidenced by the ability of camel milk to alter the expression of Cyp1a1 at the mRNA and protein levels (Figures 3 and 4).
The transcriptional regulation of Cyp1a1 and Nqo1 genes by camel milk (fat-free) was demonstrated by several lines of evidence. First, the inhibition of XRE-dependent luciferase assay that occurs only through the AhR activation suggests an AhR-dependent transcriptional control (Figure 5). Second, the ability of the transcription inhibitor, Act-D, to significantly block the newly synthesized Nqo1 mRNA (Figure 7) suggests a requirement of de novo RNA synthesis for the induction of Nqo1 mRNA by camel milk. Taken together, these results strongly suggest that the inhibition of Cyp1a1 and induction of Nqo1 genes by camel milk is mediated, at least in part, at the transcriptional level.
Interestingly, the observation that camel milk-mediated inhibition of Cyp1a1 induction by TCDD at the activity levels is higher than those observed at the protein levels (Figure 2), suggest that a possible involvement of a posttranslational mechanism, such as phosphorylation, proteasomal degradations, modulation of HO-1 gene expression, could be involved [22, 28]. Among these mechanisms, HO-1 gene expression, a rate-limiting enzyme in heme catabolism, has been shown to alter cellular heme, the prosthetic group of CYP450, content and hence the enzyme activity . To test this hypothesis, we have examined the effect of camel milk (fat-free) on the expression of Ho-1 mRNA level. Our results showed that the camel milk increases the level of Ho-1 mRNA levels (Figure 6). Taken together, we postulated here that the capacity of camel milk to induce the expression of Ho-1 mRNA resulted in a decrease in Cyp1a1 activity levels through degrading its heme content. This postulation is supported by our previous observations that in mesoporphyrin, competitive Ho-1 inhibitor or knockdown of Ho-1 using siRNA significantly restored the inhibition of Cyp1a1 activity by heavy metals [30, 31].
The chemo protective effect of camel milk was further supported, in addition to inhibition of Cyp1a1, by the ability to upregulate antioxidant genes, particularly Nqo1 and Gsta1 mRNA levels in a concentration-dependent manner (Figure 7). Our results are in agreement with previous studies that reported the ability of camel milk to induce GST levels in healthy and schistosoma-infected mice . Thus increased expression of Nqo1 and Gsta1 by camel milk will increase the levels of several antioxidant enzymes which prevent the formation of highly reactive oxygen radicals and hence reduce DNA adduct and cell damage . In addition, overexpression of NQO1 in several human solid tumors and cancer cells has been shown to activate bioreductive chemotherapeutic agents in tumor cells that allow tumor cytotoxicity without corresponding toxicity to normal cells .
Although the potential mediators in camel milk involved in the downregulation of Cyp1a1 and induction of Nqo1 and Gsta1 were not examined in this study, several previous studies have reported that camel milk contains considerably higher amounts of antioxidant vitamins, such as E and C, in comparison to cow milk , lysosomes , lactoferrins [11, 36], and immunoglobulines . In addition, ongoing research in our laboratory has shown the presence of several compounds in camel milk that could be involved in milk-mediated effect (unpublished data). Among these mediators, lactoferrin, an iron-binding glycoprotein, is known to exert in vitro and in vivo antitumor activity . In this context, it has been recently reported that lactoferrin inhibits the development of cancer through inhibiting CYP1A1 activation in 7,12-dimethylbenz[a]anthracene- (DMBA-) induced hamster buccal pouch carcinoma model. Taken together the results obtained from our laboratory and previously published reports, we speculate that lactoferrin could be responsible for camel-milk-mediated effect. In addition, the main components of the camel milk have been already determined . Ongoing research in our laboratory focuses on identifying and characterizing the most effective component of camel milk using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and one-dimensional gel electrophoresis, where several proteins were found to be relatively abundant in camel milk (data not shown).
In conclusion, the results of current study suggest that camel milk could protect against or decrease the deleterious effects of many environmental toxicants and carcinogens such as PAHs, probably through modulation of AhR-regulated genes of Cyp1a1, Nqo1, and Gsta1 at the transcriptional and posttranscriptional mechanisms. These results are of potential clinical significance to humans in that it uncovers the molecular mechanism involved and could explain the anecdotal evidence for the successful use of camel milk in the treatment and/or prevention of various medical conditions.
|AhR:||Aryl hydrocarbon receptor|
|CYP1A1:||Cytochrome P450 1A1|
|Gsta1:||Glutathione S-transferase a1|
|MTT:||(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)|
|PAHs:||Polycyclic aromatic hydrocarbons|
|XRE:||Xenobiotic responsive element.|
Conflict of Interests
The authors declare that there is no conflict of interests.
The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group project no. RGP-VPP-141.
- J. K. Kerzee and K. S. Ramos, “Constitutive and inducible expression of Cyp1a1 and Cyp1b1 in vascular smooth muscle cells: role of the Ahr bHLH/PAS transcription factor,” Circulation Research, vol. 89, no. 7, pp. 573–582, 2001.
- M. L. Whitelaw, M. Gottlicher, J. A. Gustafsson, and L. Poellinger, “Definition of a novel ligand binding domain of a nuclear bHLH receptor: co-localization of ligand and hsp90 binding activities within the regulable inactivation domain of the dioxin receptor,” EMBO Journal, vol. 12, no. 11, pp. 4169–4179, 1993.
- J. P. Whitlock Jr., “Induction of cytochrome P4501A1,” Annual Review of Pharmacology and Toxicology, vol. 39, pp. 103–125, 1999.
- D. W. Nebert, A. L. Roe, M. Z. Dieter, W. A. Solis, Y. Yang, and T. P. Dalton, “Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis,” Biochemical Pharmacology, vol. 59, no. 1, pp. 65–85, 2000.
- D. W. Nebert, T. P. Dalton, A. B. Okey, and F. J. Gonzalez, “Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer,” Journal of Biological Chemistry, vol. 279, no. 23, pp. 23847–23850, 2004.
- D. Ross, “Quinone reductases multitasking in the metabolic world,” Drug Metabolism Reviews, vol. 36, no. 3-4, pp. 639–654, 2004.
- V. Vasiliou, D. Ross, and D. W. Nebert, “Update of the NAD(P)H:Quinone oxidoreductase (NQO) gene family,” Human Genomics, vol. 2, no. 5, pp. 329–335, 2006.
- M. Cuendet, C. P. Oteham, R. C. Moon, and J. M. Pezzuto, “Quinone reductase induction as a biomarker for cancer chemoprevention,” Journal of Natural Products, vol. 69, no. 3, pp. 460–463, 2006.
- N. Kontou, T. Psaltopoulou, D. Panagiotakos, M. A. Dimopoulos, and A. Linos, “The mediterranean diet in cancer prevention: a review,” Journal of Medicinal Food, vol. 14, no. 10, pp. 1065–1078, 2011.
- C. Conesa, L. Sánchez, C. Rota et al., “Isolation of lactoferrin from milk of different species: calorimetric and antimicrobial studies,” Comparative Biochemistry and Physiology B, vol. 150, no. 1, pp. 131–139, 2008.
- E. I. el Agamy, R. Ruppanner, A. Ismail, C. P. Champagne, and R. Assaf, “Antibacterial and antiviral activity of camel milk protective proteins,” Journal of Dairy Research, vol. 59, no. 2, pp. 169–175, 1992.
- C. Saravanan, Z. Cao, J. Kumar, et al., “Milk components inhibit Acanthamoeba-induced cytopathic effect,” Investigative Ophthalmology & Visual Science, vol. 49, no. 3, pp. 1010–1015, 2008.
- H. M. Korashy and A. O. S. El-Kadi, “The role of aryl hydrocarbon receptor and the reactive oxygen species in the modulation of glutathione transferase by heavy metals in murine hepatoma cell lines,” Chemico-Biological Interactions, vol. 162, no. 3, pp. 237–248, 2006.
- S. W. Kennedy, A. Lorenzen, C. A. James, and B. T. Collins, “Ethoxyresorufin-O-deethylase and porphyrin analysis in chicken embryo hepatocyte cultures with fluorescence multiwell plate reader,” Analytical Biochemistry, vol. 211, no. 1, pp. 102–112, 1993.
- A. Lorenzen and S. W. Kennedy, “A fluorescence-based protein assay for use with a microplate reader,” Analytical Biochemistry, vol. 214, no. 1, pp. 346–348, 1993.
- B. N. M. Zordoky, M. E. Aboutabl, and A. O. S. El-Kadi, “Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats,” Drug Metabolism and Disposition, vol. 36, no. 11, pp. 2277–2286, 2008.
- A. Anwar-Mohamed, O. S. Degenhardt, M. A. M. El Gendy, J. M. Seubert, S. R. Kleeberger, and A. O. S. El-Kadi, “The effect of Nrf2 knockout on the constitutive expression of drug metabolizing enzymes and transporters in C57Bl/6 mice livers,” Toxicology in Vitro, vol. 25, no. 4, pp. 785–795, 2011.
- A. Anwar-Mohamed, R. H. Elbekai, and A. O. S. El-Kadi, “MG-132 inhibits the TCDD-mediated induction of Cyp1a1 at the catalytic activity but not the mRNA or protein levels in Hepa 1c1c7 cells,” Toxicology Letters, vol. 182, no. 1-3, pp. 121–126, 2008.
- K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
- J. Sambrook, E. F. Fritsch, and T. Maniatatis, “Molecular Cloning,” in A Laboratory Manual, N. Ford, Ed., Cold Spring Harbour Laboratory Press, Plainview, NY, USA, 1989.
- M. A. M. El Gendy, A. A. Soshilov, M. S. Denison, and A. O. S. El-Kadi, “Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol,” Toxicology Letters, vol. 208, no. 1, pp. 51–61, 2012.
- H. M. Korashy and A. O. S. El-Kadi, “Regulatory mechanisms modulating the expression of cytochrome P450 1A1 gene by heavy metals,” Toxicological Sciences, vol. 88, no. 1, pp. 39–51, 2005.
- M. L. Slattery, W. Samowtiz, K. Ma et al., “CYP1A1, cigarette smoking, and colon and rectal cancer,” American Journal of Epidemiology, vol. 160, no. 9, pp. 842–852, 2004.
- P. P. Shah, K. Saurabh, M. C. Pant, N. Mathur, and D. Parmar, “Evidence for increased cytochrome P450 1A1 expression in blood lymphocytes of lung cancer patients,” Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, vol. 670, no. 1-2, pp. 74–78, 2009.
- T. Shimada and Y. Fujii-Kuriyama, “Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1,” Cancer Science, vol. 95, no. 1, pp. 1–6, 2004.
- T. D. Williams, J. S. Lee, D. L. Sheader, and J. K. Chipman, “The cytochrome P450 1A gene (CYP1A) from European flounder (Platichthys flesus), analysis of regulatory regions and development of a dual luciferase reporter gene system,” Marine Environmental Research, vol. 50, no. 1–5, pp. 1–6, 2000.
- B. Hasspieler, D. Haffner, M. Stelljes, and K. Adeli, “Toxicological assessment of industrial solvents using human cell bioassays: assessment of short-term cytotoxicity and long-term genotoxicity potential,” Toxicology and Industrial Health, vol. 22, no. 7, pp. 301–315, 2006.
- V. Werlinder, M. Backlund, A. Zhukov, and M. Ingelman-Sundberg, “Transcriptional and post-translational regulation of CYP1A1 by primaquine,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 1, pp. 206–214, 2001.
- G. Kikuchi, T. Yoshida, and M. Noguchi, “Heme oxygenase and heme degradation,” Biochemical and Biophysical Research Communications, vol. 338, no. 1, pp. 558–567, 2005.
- I. E. A. Amara, A. Anwar-Mohamed, and A. O. S. El-Kadi, “Mercury modulates the CYP1A1 at transcriptional and posttranslational levels in human hepatoma HepG2 cells,” Toxicology Letters, vol. 199, no. 3, pp. 225–233, 2010.
- A. Anwar-Mohamed and A. O. S. El-Kadi, “Arsenite down-regulates cytochrome P450 1A1 at the transcriptional and posttranslational levels in human HepG2 cells,” Free Radical Biology and Medicine, vol. 48, no. 10, pp. 1399–1409, 2010.
- A. S. Maghraby, M. A. Mohamed, and A. M. Abdel-Salam, “Anti-schistosomal activity of colostral and mature camel milk on Schistosoma mansoni infected mice,” Asia Pacific Journal of Clinical Nutrition, vol. 14, no. 4, pp. 432–438, 2005.
- M. Mohora, “Role of Nad(P)h: quinone oxidoreductase in the regulation of intracellular redox state,” Romanian Journal of Internal Medicine, vol. 38-39, pp. 33–50, 2000.
- S. Danson, T. H. Ward, J. Butler, and M. Ranson, “DT-diaphorase: a target for new anticancer drugs,” Cancer Treatment Reviews, vol. 30, no. 5, pp. 437–449, 2004.
- Z. Farah, R. Rettenmaier, and D. Atkins, “Vitamin content of camel milk,” International Journal for Vitamin and Nutrition Research, vol. 62, no. 1, pp. 30–33, 1992.
- G. Konuspayeva, B. Faye, G. Loiseau, and D. Levieux, “Lactoferrin and immunoglobulin contents in camel's milk (Camelus bactrianus, Campus dromedarius, and Hybrids) from Kazakhstan,” Journal of Dairy Science, vol. 90, no. 1, pp. 38–46, 2007.
- A. Roseanu, P. E. Florian, M. Moisei, L. E. Sima, R. W. Evans, and M. Trif, “Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells,” BioMetals, vol. 23, no. 3, pp. 485–492, 2010.
- M. S. Y. Haddadin, S. I. Gammoh, and R. K. Robinson, “Seasonal variations in the chemical composition of camel milk in Jordan,” Journal of Dairy Research, vol. 75, no. 1, pp. 8–12, 2008.